special stage IIIB non-small-cell lung cancer
Conditions
Interventions
Control group:Traditional concurrent chemotherapy plus radiotherapy
Experimental group:Supraclavicaular lymph nodes dissection
Sponsors
Cancer Hospital Affiliated to Tianjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Special stage IIIB non-small-cell lung cancer diagnosed by histology and pathology/cytology on first- time treatment; definition of special stage IIIb: T: T1,T2,T3; N: supraclavicular lymph nodes metastasis, excluding other N3; M: M0; 2. At least one focus with two diameters measurable, spiral CT scanning more greater than 10 mm; 3. In good physical condition: ECOG score 0-2 points; 4. Predicted survival longer than 3 months; 5. Age over 18 years, non-limited gender; 6. In accordance with the clinical application and basic request including normal peripheric hemogram, normal function of heart, liver and kidney, essentially normal ECG and without unhealing trauma; Laboratory index must meet with following requests: Peripheric hemogram: WBC more than 4.0*10^9/L, PLT more than 80*10^9/L, Hb more than 90g/L; Renal function: Cr<=2.0*UNL (normal upper limit); Liver function: BIL less than 2.0*UNL, ALT/AST less than 5.0*UNL; 7. Participated with free will and good compliance, easy to cooperate in trial observation and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Other stage IIIB non-small-cell lung cancer unqualified in this trial; 2. Pregnant or breast-feeding women or female in reproductive stage without birth control; 3. Severe acute infection out of control; purulent chronic infection with chronic nonunion wound; 4. Complicated with severe heart disease including congestive heart failure, uncontrolled fatal arrhythmia, unstable angina, myocardial infarction, severe heart valve disease and resistant hypertension; 5. With uncontrolled neural and mental disorder and poor compliance, unable to cooperate and recount the therapeutic response; primary encephaloma or uncontrolled metastatic tumor of the central nervous system with evident intracranial hypertension or neuropsychiatric symptoms; 6. Participated in other clinical trial at the same time; 7. Other inappropriate conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Cost-Benefit analysis; | — |
Countries
China
Contacts
Public ContactZhanyu Pan; Changli Wang
Outcome results
None listed